Diebold Nixdorf vs Omnicell
DBD and OMCL side by side, both in computer and office equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DBD and OMCL compare
Diebold Nixdorf is the larger company, worth 1.2 times as much as Omnicell ($1.8B against $1.6B).
On earnings, Diebold Nixdorf is cheaper: it trades at 25.6× trailing earnings, against 36.0× for Omnicell.
Diebold Nixdorf grew revenue faster over the last twelve months (6.3% versus 5.6% for Omnicell).
Omnicell keeps more of each dollar of sales as profit, with a net margin of 3.6% compared with 2.0% at Diebold Nixdorf.
Omnicell scores higher on the StockData Score (13 against 8 for Diebold Nixdorf), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DBD | OMCL |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $1.6B |
| Share price | $54.75 | $34.95 |
| Change, 1 year | −16.1% | −5.8% |
| Change, 5 years | – | −80.9% |
| Beta (5Y) | 0.96 | 0.82 |
| Employees | 20K | 3,580 |
| StockData Score | ||
| Total score | 8 | 13 (better) |
| Valuation score | 5 | 5 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 25.6× (better) | 36.0× |
| P/S | 0.5× (better) | 1.3× |
| P/B | 2.0× | 1.2× (better) |
| EV/EBITDA | 7.8× (better) | 9.1× |
| P/FCF | – | 10.9× |
| FCF yield | – | 9.1% |
| Fair value | $92.75 | $55.29 |
| Margin of safety | 41.0% (better) | 36.8% |
| Growth | ||
| Revenue growth (TTM) | 6.3% (better) | 5.6% |
| Revenue growth, 5Y average | −0.50% | 5.8% (better) |
| Net income growth (TTM) | 51.6% | 124% (better) |
| EPS growth (TTM) | 56.2% | 126% (better) |
| EPS growth, 5Y average | – | −44.2% |
| Profitability | ||
| Gross margin | 25.0% | 45.1% (better) |
| Operating margin | 5.4% (better) | 5.2% |
| Net margin | 2.0% | 3.6% (better) |
| FCF margin | – | 11.7% |
| Return on equity | 7.5% (better) | 3.5% |
| Return on invested capital | 8.1% (better) | 4.2% |
| Financial health | ||
| Debt / equity | 1.01 (better) | 0.00 |
| Net debt / EBITDA | 2.28 | – |
| Interest coverage | 2.2× | – |
| Current ratio | 1.27 | 1.66 (better) |
| Altman Z-score | 1.83 | 2.48 (better) |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | 11.2% | – |
| Shareholder yield | 11.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 116% | 106% |
| Held by insiders | 58.9% | 3.3% |
| Insider net buying, 12 months | −$126M | −$2.9M (better) |
| Short interest, % of float | 23.0% | 8.6% |
Go deeper
- DBD stock overview
- DBD income statement
- DBD valuation and score
- OMCL stock overview
- OMCL income statement
- OMCL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.